Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) EPS (Basic) (2021 - 2025)

SAB Biotherapeutics' EPS (Basic) history spans 5 years, with the latest figure at -$0.51 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 58.54% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$1.66, up 54.89%, while the annual FY2025 figure was $0.22, 105.98% up from the prior year.
  • EPS (Basic) reached -$0.51 in Q4 2025 per SABSW's latest filing, down from $0.5 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.5 in Q3 2025 to a low of -$3.85 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$0.7, with a median of -$0.52 recorded in 2024.
  • Peak YoY movement for EPS (Basic): crashed 7400.0% in 2023, then skyrocketed 144.64% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.41 in 2021, then surged by 56.1% to -$0.18 in 2022, then tumbled by 2038.89% to -$3.85 in 2023, then soared by 68.05% to -$1.23 in 2024, then skyrocketed by 58.54% to -$0.51 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's EPS (Basic) are -$0.51 (Q4 2025), $0.5 (Q3 2025), and -$1.09 (Q2 2025).